Deintensification of adjuvant treatment after transoral surgery in patients with human papillomavirus-positive oropharyngeal cancer: the conception of the PATHOS study and its development
Deintensification of adjuvant treatment after transoral surgery in patients with human papillomavirus-positive oropharyngeal cancer: the conception of the PATHOS study and its development
PATHOS is a phase II/III randomized controlled trial (RCT) of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery (TOS) for human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). The study opened in the UK in October 2015 and, after successful recruitment into the phase II, transitioned into phase III in the autumn of 2018. PATHOS aims to establish whether the de-intensification of adjuvant treatment in patients with favorable prognosis HPV-positive OPSCC will confer improved swallowing outcomes, whilst maintaining high rates of cure. In this article, we will outline the rationale for the study and how it aims to answer fundamentally important questions about the safety, effectiveness and functional outcomes of minimally invasive TOS techniques followed by adjuvant radiotherapy (RT) or chemo-radiotherapy (CRT) in this patient population.
Hargreaves, Sarah
2b29829d-2f61-4f05-88a4-ac532a93c3fa
Beasley, Matthew
83d76e34-edee-40f8-88b1-5849c98c9d83
Hurt, Chris
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
Jones, Terry M.
919616d1-c376-4cee-8fde-7476e46af665
Evans, Mererid
4c523461-bb6c-40be-8b27-a6bd29ba8b89
1 October 2019
Hargreaves, Sarah
2b29829d-2f61-4f05-88a4-ac532a93c3fa
Beasley, Matthew
83d76e34-edee-40f8-88b1-5849c98c9d83
Hurt, Chris
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
Jones, Terry M.
919616d1-c376-4cee-8fde-7476e46af665
Evans, Mererid
4c523461-bb6c-40be-8b27-a6bd29ba8b89
Hargreaves, Sarah, Beasley, Matthew, Hurt, Chris, Jones, Terry M. and Evans, Mererid
(2019)
Deintensification of adjuvant treatment after transoral surgery in patients with human papillomavirus-positive oropharyngeal cancer: the conception of the PATHOS study and its development.
Frontiers in Oncology, 9, [936].
(doi:10.3389/fonc.2019.00936).
Abstract
PATHOS is a phase II/III randomized controlled trial (RCT) of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery (TOS) for human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). The study opened in the UK in October 2015 and, after successful recruitment into the phase II, transitioned into phase III in the autumn of 2018. PATHOS aims to establish whether the de-intensification of adjuvant treatment in patients with favorable prognosis HPV-positive OPSCC will confer improved swallowing outcomes, whilst maintaining high rates of cure. In this article, we will outline the rationale for the study and how it aims to answer fundamentally important questions about the safety, effectiveness and functional outcomes of minimally invasive TOS techniques followed by adjuvant radiotherapy (RT) or chemo-radiotherapy (CRT) in this patient population.
Text
fonc-09-00936
- Version of Record
More information
Accepted/In Press date: 6 September 2019
Published date: 1 October 2019
Identifiers
Local EPrints ID: 488211
URI: http://eprints.soton.ac.uk/id/eprint/488211
ISSN: 2234-943X
PURE UUID: 8cfe3af3-f0df-44ec-bc33-938e1e1b193c
Catalogue record
Date deposited: 18 Mar 2024 17:54
Last modified: 23 Mar 2024 03:13
Export record
Altmetrics
Contributors
Author:
Sarah Hargreaves
Author:
Matthew Beasley
Author:
Chris Hurt
Author:
Terry M. Jones
Author:
Mererid Evans
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics